Darunavir
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Darunavir and local guidelines before prescribing.
Protease inhibitor
Mechanism
Protease inhibitor (boosted).
Uses
HIV infection.
Dosing
- 4. A 52-year-old man with HIV, well controlled on darunavir with cobicistat plus two NRTIs, is started on simvastatin 40 mg by his GP and uses a fluticasone nasal spray for rhinitis. Two months later he has muscle pain, weight gain and a round face. Answer: CYP3A4 interactions - statin myopathy and iatrogenic Cushing's syndrome with …
ID: HIV, viral hepatitis and blood-borne viruses
Side effects
Diarrhoea, nausea, rash, raised lipids.
Interactions
Boosted: many CYP3A4 interactions.
Contraindications and cautions
Severe liver impairment
Monitoring
LFT, lipids
Pregnancy and breastfeeding
Used in pregnancy
Renal and hepatic impairment
Avoid in severe hepatic impairment
Overdose and reversal
Supportive
Special advice
Sulfonamide allergy caution.
More from the textbook: uses, cautions and other points
- Protease inhibitors (boosted) | Darunavir with ritonavir or cobicistat | GI upset, raised lipids; the boosters (ritonavir, cobicistat) are strong CYP3A4 inhibitors - many interactions
ID: HIV, viral hepatitis and blood-borne viruses - Darunavir with ritonavir or cobicistat | Boosted PI; strong CYP3A4 inhibition - no simvastatin; fluticasone causes Cushing's.
ID: HIV, viral hepatitis and blood-borne viruses - Protein processing | Protease inhibitors (darunavir, nirmatrelvir with ritonavir - Paxlovid; glecaprevir for HCV) | HIV, COVID-19, HCV
Microbiology: Virology - structure, replication and important viral infections